merck & co. news - Search News

Merck Discontinues Certain Cancer Candidate Trials

Merck Discontinues Certain Cancer Candidate Trials After Futility Analysis

Merck & Co Inc (NYSE:MRK) revealed that it would discontinue the clinical development programs for vibostolimab and favezelimab. Vibostolimab is being evaluated as an investigational fixed-dose combination with Keytruda (pembrolizumab) in the KeyVibe program.

FierceBiotech · 1d

Merck drops TIGIT asset and LAG-3 program, discontinuing several phase 3 trials

Out with the old, in with the new. The end of the year in biopharma is typically marked by pipeline clear outs, and 2024 is proving that it’s no different. | In a day that already included discontinuations from Roche and Foghorn Therapeutics,

Reuters · 17h

Merck discontinues development of 2 experimental cancer drugs after trial failures

Merck said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several trials.

Business Insider · 1d

Merck to discontinue Phase 3 KeyVibe-003, KeyVibe-007 trials

Merck (MRK) announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an

Merck targets 2025 RSV season

Yahoo · 19h

Merck targets 2025 RSV season with antibody now under FDA review

An FDA approval of Merck’s drug clesrovimab by June would give physicians another option for protecting newborns from respiratory syncytial virus.

Business Insider · 19h

Merck: FDA To Review BLA For Clesrovimab - Quick Facts

Merck (MRK) announced the FDA has accepted the Biologics License Application for clesrovimab, or MK-1654, the company's

MarketWatch · 20h

Merck Gets FDA Review of Clesrovimab RSV Vaccine Candidate

Merck & Co. on Tuesday said the Food and Drug Administration has accepted its application seeking approval of its proposed clesrovimab vaccine aimed at protecting infants from respiratory syncytial virus,

10h

Merck & Co. Inc. stock remains steady Tuesday, still outperforms market

Shares of Merck & Co. Inc. MRK were unchanged Tuesday, on what proved to be an all-around dismal trading session for the ...

19hon MSN

Is Merck & Co., Inc. (MRK) the Best Weight Loss Stock to Buy Now According to Hedge Funds?

We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going ...

Merck calls quits on two immunotherapies for cancer

The company is scrapping two drugs aimed at targets called TIGIT and LAG-3, both of which were in the middle of Phase 3 ...

Merck Has Become Very Cheap Again

Merck has become inexpensive again and combines a good growth outlook with a nice and growing dividend. Learn why MRK stock ...

Merck & Co. Inc. stock outperforms competitors despite losses on the day

Shares of Merck & Co. Inc. MRK slipped 1.12% to $100.06 Monday, on what proved to be an all-around mixed trading session for ...

Yahoo Finance2d

Merck & Co., Inc. (MRK)

AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc (NYSE:MRK), on Wednesday, announced long-term results from the OlympiA Phase 3 trial. The trial showed Lynparza (olaparib) demonstrated sustained ...

The Pharma Letter12h

Merck & Co’s clesrovimab BLA accepted by FDA

The US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for clesrovimab (MK-1654), ...

China Approves Merck's Keytruda To Treat Patients With Resectable Stage II, IIIA Or IIIB NSCLC

(RTTNews) - Merck & Co Inc. (MRK), Monday said China's National Medical Products Administration (NMPA) has approved Keytruda in combination with chemo therapy as neoadjuvant treatment, then as ...

Is Merck & Co., Inc. (MRK) the Best American Dividend Stock to Buy Right Now?

We recently compiled a list of the 8 Best American Dividend Stocks To Buy Right Now. In this article, we are going to take a ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results